Glycogen Storage Disease Type II
"Glycogen Storage Disease Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)
Descriptor ID |
D006009
|
MeSH Number(s) |
C10.228.140.163.100.435.340 C16.320.565.189.435.340 C16.320.565.202.449.500 C16.320.565.595.554.340 C18.452.132.100.435.340 C18.452.648.189.435.340 C18.452.648.202.449.500 C18.452.648.595.554.340
|
Concept/Terms |
Glycogen Storage Disease Type II- Glycogen Storage Disease Type II
- Acid Maltase Deficiency Disease
- Deficiency Disease, Acid Maltase
- Deficiency Disease, Lysosomal alpha-1,4-Glucosidase
- GAA Deficiency
- Deficiencies, GAA
- Deficiency, GAA
- GAA Deficiencies
- Generalized Glycogenosis
- Generalized Glycogenoses
- Glycogenoses, Generalized
- Glycogenosis, Generalized
- Glycogen Storage Disease II
- Glycogen Storage Disease Type 2
- Glycogenosis 2
- Glycogenosis Type II
- Type II, Glycogenosis
- Type IIs, Glycogenosis
- GSD II
- Lysosomal alpha-1,4-Glucosidase Deficiency Disease
- Lysosomal alpha 1,4 Glucosidase Deficiency Disease
- Pompe Disease
- Disease, Pompe
- Pompe's Disease
- Disease, Pompe's
- Pompes Disease
- Deficiency of Alpha-Glucosidase
- Alpha-Glucosidase Deficiencies
- Alpha-Glucosidase Deficiency
- Deficiency of Alpha Glucosidase
- GSD2
- GSD2s
- Acid Alpha-Glucosidase Deficiency
- Acid Alpha Glucosidase Deficiency
- Acid Alpha-Glucosidase Deficiencies
- Alpha-Glucosidase Deficiencies, Acid
- Alpha-Glucosidase Deficiency, Acid
- Deficiencies, Acid Alpha-Glucosidase
- Deficiency, Acid Alpha-Glucosidase
Acid Maltase Deficiency- Acid Maltase Deficiency
- Acid Maltase Deficiencies
- Deficiencies, Acid Maltase
- Deficiency, Acid Maltase
- Maltase Deficiencies, Acid
- Alpha-1,4-Glucosidase Deficiency
- Alpha 1,4 Glucosidase Deficiency
- Alpha-1,4-Glucosidase Deficiencies
- Deficiencies, Alpha-1,4-Glucosidase
- Deficiency, Alpha-1,4-Glucosidase
|
Below are MeSH descriptors whose meaning is more general than "Glycogen Storage Disease Type II".
- Diseases [C]
- Nervous System Diseases [C10]
- Central Nervous System Diseases [C10.228]
- Brain Diseases [C10.228.140]
- Brain Diseases, Metabolic [C10.228.140.163]
- Brain Diseases, Metabolic, Inborn [C10.228.140.163.100]
- Lysosomal Storage Diseases, Nervous System [C10.228.140.163.100.435]
- Glycogen Storage Disease Type II [C10.228.140.163.100.435.340]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Metabolism, Inborn Errors [C16.320.565]
- Brain Diseases, Metabolic, Inborn [C16.320.565.189]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.189.435]
- Glycogen Storage Disease Type II [C16.320.565.189.435.340]
- Carbohydrate Metabolism, Inborn Errors [C16.320.565.202]
- Glycogen Storage Disease [C16.320.565.202.449]
- Glycogen Storage Disease Type II [C16.320.565.202.449.500]
- Lysosomal Storage Diseases [C16.320.565.595]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.595.554]
- Glycogen Storage Disease Type II [C16.320.565.595.554.340]
- Nutritional and Metabolic Diseases [C18]
- Metabolic Diseases [C18.452]
- Brain Diseases, Metabolic [C18.452.132]
- Brain Diseases, Metabolic, Inborn [C18.452.132.100]
- Lysosomal Storage Diseases, Nervous System [C18.452.132.100.435]
- Glycogen Storage Disease Type II [C18.452.132.100.435.340]
- Metabolism, Inborn Errors [C18.452.648]
- Brain Diseases, Metabolic, Inborn [C18.452.648.189]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.189.435]
- Glycogen Storage Disease Type II [C18.452.648.189.435.340]
- Carbohydrate Metabolism, Inborn Errors [C18.452.648.202]
- Glycogen Storage Disease [C18.452.648.202.449]
- Glycogen Storage Disease Type II [C18.452.648.202.449.500]
- Lysosomal Storage Diseases [C18.452.648.595]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.595.554]
- Glycogen Storage Disease Type II [C18.452.648.595.554.340]
Below are MeSH descriptors whose meaning is more specific than "Glycogen Storage Disease Type II".
This graph shows the total number of publications written about "Glycogen Storage Disease Type II" by people in this website by year, and whether "Glycogen Storage Disease Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 2 | 0 | 2 |
2016 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycogen Storage Disease Type II" by people in Profiles.
-
Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021 05; 23(5):845-855.
-
Glycogen accumulation in smooth muscle of a Pompe disease mouse model. J Smooth Muscle Res. 2021; 57(0):8-18.
-
The Respiratory Phenotype of Pompe Disease Mouse Models. Int J Mol Sci. 2020 Mar 24; 21(6).
-
Complementary Starch Feeding of the Young Child: Starch Digestion Consortium Workshop 18. J Pediatr Gastroenterol Nutr. 2018 06; 66 Suppl 3:S1-S3.
-
AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease. Sci Rep. 2017 11 08; 7(1):15089.
-
Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease. Am J Med Genet A. 2017 Sep; 173(9):2500-2504.
-
Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy. Echocardiography. 2017 Apr; 34(4):621-624.
-
Long-term, high-level hepatic secretion of acid a-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus. Gene Ther. 2016 10; 23(10):743-752.
-
What else is in store for autophagy? Exocytosis of autolysosomes as a mechanism of TFEB-mediated cellular clearance in Pompe disease. Autophagy. 2013 Jul; 9(7):1117-8.
-
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med. 2013 May; 5(5):691-706.